On April 6, 2026, Citizens began coverage of Avalo Therapeutics (NasdaqCM: AVTX) with a “Market Outperform” recommendation. The average one-year price target for Avalo is projected at $36.95 per share, representing a potential increase of 108.03% from its recent closing price of $17.76.
Additionally, Avalo Therapeutics is projected to achieve annual revenues of $71 million, a staggering increase of 120,018.64%. There are currently 87 funds holding positions in Avalo, showing a 14.47% increase in ownership over the last quarter; total institutional shares rose by 25.52% to 19.37 million shares. The put/call ratio stands at 0.32, indicating a bullish sentiment towards the stock.
